2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -2.56%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Hypera Sp ADR (HYPMY)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 68
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Statistics
MoreInformation as of 06/03/2026
Company Profile
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Key Executives
- Rafael Vito Batista
- Luiz Eduardo Sales Clavis
- Hélio Segouras
- Breno Toledo Pires de Oliveira
- Ramon Sanches Frutuoso Silva
Current Ownership Distribution
- Other700.5M (99.57%)
- Institutions2.6M (0.37%)
- Mutual Funds403,449 (0.06%)
- Insiders0 (0.00%)